Seqens announces China investment
Seqens is to make an investment of nearly RMB 300 million (€40 million) in three major new production capacity projects for the healthcare and cosmetics markets at Taixing and Wuxi, China. CEO Pierre Luzeau (pictured) announced this during a meeting President Macron had with between President Xi Jinping and Macron in Beijing on 6 April.
“These three projects will complement Seqens' industrial facilities and investments in Europe with sustainable and competitive production closer to local markets and will support the growing demand of the healthcare and cosmetics markets for safe and sustainable products,” the company stated. No further details have yet been disclosed.
RELATED ARTICLES
Two CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
CatSci has opened a second oligonucleotides laboratory, which it will use “to introduce novel workflows for the rapid production of vast numbers of oligos at a scale optimised for rapid screening”.
Swedish-based CDMO Recipharm announced at CPHI that it is “expanding its pharmaceutical development capabilities through targeted investments and the integration of cutting-edge technologies”.
